MYC and neoplasm: Considering the observed deficiency of T cells in Myc-CaP tumors (Figure 5A), we hypothesized that anti-PD1 therapy might not effectively suppress Myc-CaP tumor growth, and anticipated that inhibiting Gal-1 with LLS30 could enhance the efficacy of anti-PD1 therapy by improving T cell infiltration.